PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
28.38%
Revenue growth above 1.5x CVE's 1.92%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
46.50%
Positive gross profit growth while CVE is negative. John Neff would see a clear operational edge over the competitor.
202.59%
Positive EBIT growth while CVE is negative. John Neff might see a substantial edge in operational management.
202.59%
Positive operating income growth while CVE is negative. John Neff might view this as a competitive edge in operations.
125.83%
Net income growth above 1.5x CVE's 42.34%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
125.00%
EPS growth above 1.5x CVE's 41.18%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
125.32%
Diluted EPS growth above 1.5x CVE's 41.18%. David Dodd would see if there's a robust moat protecting these shareholder gains.
1.20%
Share change of 1.20% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
-0.51%
Reduced diluted shares while CVE is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-1.19%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
86.32%
OCF growth at 50-75% of CVE's 136.21%. Martin Whitman would question if the firm lags in monetizing sales effectively.
401.67%
FCF growth similar to CVE's 396.00%. Walter Schloss would attribute it to parallel capital spending and operational models.
-90.79%
Negative 10Y revenue/share CAGR while CVE stands at 21.93%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-29.92%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-15.32%
Negative 3Y CAGR while CVE stands at 25.93%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-77.27%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-26.83%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
71.99%
3Y OCF/share CAGR 1.25-1.5x CVE's 57.52%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-99.14%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-83.96%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
102.78%
Positive short-term CAGR while CVE is negative. John Neff would see a clear advantage in near-term profit trajectory.
-78.42%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-7.26%
Negative 5Y equity/share growth while CVE is at 13.35%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-14.91%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
-96.32%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-89.89%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-67.57%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-16.54%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-1.23%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-0.03%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-9.70%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.